T-cell ligands modulate the cytolytic activity of the CD33/CD3 BiTE antibody construct, AMG 330

Preclinical and emerging clinical studies demonstrate that bispecific T-cell engaging (BiTE) antibody constructs can potently lyse targeted tumor cells, but the determinants for their activity remain incompletely understood. Using human acute myeloid leukemia (AML) cell lines engineered to overexpre...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Blood Cancer J
Autors principals: Laszlo, G S, Gudgeon, C J, Harrington, K H, Walter, R B
Format: Artigo
Idioma:Inglês
Publicat: Nature Publishing Group 2015
Matèries:
Original Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4558592/
https://ncbi.nlm.nih.gov/pubmed/26295610
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bcj.2015.68
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars